Everbright Health, a tech-enabled services platform that helps mental health providers, has launched with $7 million in seed funding from W Health Ventures and Sanos Capital.
Founded by Ben Kuhn, Ginger Holguin and Daniel Judd, Everbright Health enables mental health providers to bring advanced interventions into everyday care. Everbright Health is a division of Careforce, Inc.
Everbright supports mental health providers, such as psychiatrists, psychologists, and therapists, who want an integrated approach to care for their patients, where advanced treatments can be combined with medications and talk therapy to personalize care and dramatically improve outcomes for even the hardest-to-treat patients.
The company embeds complete clinical programs – such as transcranial magnetic stimulation (TMS), SPRAVATO, and others – into existing practices through a specialized tech-enabled services platform.
Everbright provides all the infrastructure, technology, and operations required to launch, manage, and scale these programs successfully.
deliver advanced interventions as part of everyday care, today announced its company launch with a $7 million seed investment and partnerships with over 75 providers across seven markets.
Ben Kuhn, Co-founder and CEO at Everbright Health, said, “Mental health care has made real progress in expanding access to therapy and medications. But for millions of people, they need more. We’re building a future where every mental health provider can deliver a full spectrum of care, including advanced interventions that many patients need to get better.”
Dr Pankaj Jethwani, Managing Partner at W Health Ventures, said, “We’re bullish on tech-enabled, asset-light management services organizations. This model makes it possible to build genuine partnerships with clinicians rather than compete with or employ them. When we couldn’t find one in psychiatry, we built it ourselves. Advanced psychiatric interventions are on the cusp of becoming mainstream care. With remarkable outcomes, we believe they are poised to have their own ‘GLP-1’ moment for market adoption.”
